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Abstract
Background: Aortic valve replacement is one of the most common cardiac surgical procedures performed
worldwide. Conventional aortic valve replacement surgery is performed via a median sternotomy; the sternum is
divided completely from the sternal notch to the xiphisternum. Minimally invasive aortic valve replacement, using a
new technique called manubrium-limited ministernotomy, divides only the manubrium from the sternal notch to 1
cm below the manubrio-sternal junction.
More than one third of patients undergoing conventional sternotomy develop clinically significant bleeding requiring
post-operative red blood cell transfusion. Case series data suggest a potentially clinically significant difference in red
blood cell transfusion requirements between the two techniques. Given the implications for National Health Service
resources and patient outcomes, a definitive trial is needed.
Methods/design: This is a single-centre, single-blind, randomised controlled trial comparing aortic valve replacement
surgery using manubrium-limited ministernotomy (intervention) and conventional median sternotomy (usual care). Two
hundred and seventy patients will be randomised in a 1:1 ratio between the intervention and control arms, stratified by
baseline logistic EuroSCORE and haemoglobin value. Patients will be followed for 12 weeks from discharge following their
index operation. The primary outcome is the proportion of patients who receive a red blood cell transfusion post-
operatively within 7 days of surgery. Secondary outcomes include red blood cell and blood product transfusions, blood loss,
re-operation rates, sternal wound pain, quality of life, markers of inflammatory response, hospital discharge, health care
utilisation, cost and cost effectiveness and adverse events.
Discussion: This is the first trial to examine aortic valve replacement via manubrium-limited ministernotomy versus
conventional sternotomy when comparing red blood cell transfusion rates following surgery. Surgical trials present
significant challenges; strengths of this trial include a rigorous research design, standardised surgery performed by
experienced consultant cardiothoracic surgeons, an agreed anaesthetic regimen, patient blinding and consultant-led patient
recruitment. The MAVRIC trial will demonstrate that complex surgical trials can be delivered to exemplary standards and
provide the community with the knowledge required to inform future care for patients requiring aortic valve replacement
surgery.
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Background
Aortic valve replacement (AVR)
AVR is one of the most common cardiac surgical proce-
dures performed worldwide [1, 2]. Patients suffer symp-
toms of chest pain, shortness of breath and dizziness as a
result of aortic stenosis or regurgitation. Nearly 10,000
patients undergo AVR surgery in the UK every year [2].
Patient outcomes of AVR performed in the UK from 2004
to 2009 [3] showed a 26% increase in the number of pa-
tients undergoing surgery during this period. At The
James Cook University Hospital (JCUH) in the North of
England, an audit over the same time period confirmed a
24% increase in the number of AVR operations. It is antic-
ipated that the number of AVR operations will continue
to increase.
Blood transfusion following AVR
There is significant morbidity associated with AVR sur-
gery. Consequently, blood loss and the subsequent
requirement for transfusion of red blood cells (RBCs)
and blood products are key indicators of quality. More
than one-third of patients undergoing conventional
sternotomy develop clinically significant bleeding and re-
quire a post-operative RBC transfusion [4, 5]. Blood
transfusion can have adverse clinical effects including
post-operative lung injury, organ dysfunction, confusion,
and immunosuppression [6]; complications of transfu-
sion have been directly linked to prolonged hospital stay
and increased mortality after cardiac surgery [5, 7–12].
Additionally, there is a small risk of transmitting viral in-
fection from blood donor to recipient [13]. Currently,
cardiac surgical procedures use 6% of all donor blood
available in the UK [14]. An analysis of patients over 5
years from the Society for Cardiothoracic Surgery in
Great Britain and Ireland National Database indicated
that of 41,227 patients who underwent AVR surgery,
2342 (6%) required a second operation due to excessive
bleeding [3].
Retrospective studies have shown that blood loss
and transfusion requirements are significantly less
with minimally invasive AVR [15–17]; however, most
reported using a fourth space ministernotomy incision
rather than a manubrium-limited approach. No study
thus far has tested RBC transfusion requirements in a
randomised controlled trial using manubrium-limited
ministernotomy.
Rationale for choice of comparators'
Surgical techniques in AVR
Usual care: conventional sternotomy
Conventional surgery for AVR is performed via a median
sternotomy, in which the sternum is divided completely
from the sternal notch to the xiphisternum. The oper-
ation includes cardiopulmonary bypass established by
siting cannulas in the right atrium and ascending aorta.
The heart is stopped and the valve is replaced.
Intervention under study: minimally invasive
ministernotomy
The new technique of manubrium-limited ministernotomy
divides only the top quarter of the sternum from the
sternal notch to 1 cm below the manubrio-sternal junction;
this enables access to perform the AVR. Potential benefits
may include reductions in bleeding, post-operative
pain, inflammatory response, hospital stay and time
away from work. The cardiothoracic surgical commu-
nity are enthusiastic about the procedure; however,
they are clear that definitive benefit needs to be dem-
onstrated in a randomised controlled trial before
widespread adoption of the technique.
Inflammatory markers
In minimally invasive cardiac surgical procedures, there is
less tissue trauma and the right atrium is not directly can-
nulated; conversely, cardiopulmonary bypass and aortic
cross-clamp times are longer. The mechanism for any ob-
served benefits of the minimally invasive approach is un-
confirmed, but may be due to a difference in systemic
inflammatory response (SIR). SIR can be measured by
monitoring the profile of cytokines in plasma.
This trial will determine if there is a difference in SIR
to AVR via manubrium-limited ministernotomy when
compared to conventional sternotomy by measuring
inflammatory markers at pre- and post-surgical time
points. We will seek to understand the mechanism
underlying the observations we make. Our hypothesis is
that patients who receive a sternotomy will bleed more
and require more blood transfusions. The excess bleed-
ing might be a direct result of the increased surgical
trauma or as a result of an increased SIR to sternotomy.
A SIR may have wide-ranging post-operative effects and
has previously been shown to increase atrial fibrillation
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and acute kidney injury, impair wound healing and re-
duce post-operative haemostasis [18].
Trial rationale
Case series data at The JCUH suggest a potentially signifi-
cant and clinically important difference in the need for
RBC transfusion when comparing patients undergoing
conventional and manubrium-limited surgery. Given the
implications of transfusion for National Health Service
(NHS) resources and patient outcomes, and the potential
benefits from this new technique, there is a need for a de-
finitive trial. There has been one trial in the UK evaluating
the fourth space median (minimally invasive) sternotomy
(PB-PG-0408-16296; ISRCTN 58128724); this trial is now
closed to recruitment and is in follow-up. Thus far, no
randomised trial has compared manubrium-limited minis-
ternotomy to conventional sternotomy for AVR.
The need for AVR is increasing and, with an ageing
population, the balance of surgical risk will become less
favourable given the greater level of co-morbidity in
older populations. Importantly, this new approach also
has the potential to reduce the risk of post-operative
lung injury, organ dysfunction and immunosuppression,
as well as reduce the burden on already overstretched
blood transfusion services. A robust trial of the
manubrium-limited technique compared with conven-
tional surgery is imperative and timely to ensure that ap-
propriate surgical strategies deliver improved patient
outcomes and efficient use of scarce NHS resources.
The trial will run according to the principles of Inter-
national Conference on Harmonisation (ICH)-Good
Clinical Practice (GCP) and in accordance with relevant
UK legislation and the trial protocol.
Methods/design
Objectives
This trial will investigate whether new manubrium-
limited surgery (intervention) reduces RBC transfusion
rates compared to conventional cardiac surgery (control)
for patients undergoing aortic valve replacement. The
null hypothesis is that there will be no difference in the
proportion of patients receiving RBC transfusion after
manubrium-limited ministernotomy when compared to
conventional sternotomy for AVR.
Trial design
This is a single-centre, single-blind, randomised controlled
superiority trial comparing patients undergoing AVR via
manubrium-limited ministernotomy (intervention under
study) or conventional median sternotomy (control arm/
usual care); randomisation will be performed using ran-
dom permuted blocks with a 1:1 allocation.
The manubrium-limited ministernotomy versus con-
ventional sternotomy for aortic valve replacement
(MAVRIC) trial protocol was written in accordance with
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist (see Additional file 1)
[19, 20]. The schedule of this trial is shown in Fig. 1.
Trial setting
The study aims to recruit 270 patients in a single NHS
Trust in the North of England.
Eligibility criteria
Inclusion criteria
Patients are eligible for the study if they:
1. Are aged 18 years or older at the time of consent
2. Require first-time, non-emergency, isolated AVR;
surgery
3. Are able; and willing to provide written informed
consent.
Exclusion criteria
Patients are excluded from entering the study if they:
1. Require concomitant cardiac procedure(s)
2. Have a haemoglobin level <90 g/L
3. Are pregnant; Are unable to stop currently
prescribed treatment affecting clotting
4. Have a haematological condition that would affect
participation in the trial
5. Have infective endocarditis
6. Are prevented from having RBCs and blood
products according to a system of beliefs
7. Have any other medical, psychiatric and or social
reason that precludes participation.
Eligibility check
Participants have their eligibility checked and confirmed
within the 14 days prior to surgery. Eligibility is con-
firmed by one of the three operating cardiac surgeons
who are clinical investigators for this trial.
Interventions
Manubrium-limited ministernotomy (intervention)
Manubrium-limited ministernotomy (intervention arm)
is performed using systemic normothermia. An incision
is made from the sternal notch to the second intercostal
space. The manubrium is divided longitudinally in the
midline. The sternum is then transected in both direc-
tions from the second intercostal spaces until the mid-
line incision is reached, creating a V shape. This
procedure is depicted in Fig. 2. Aortic cannulation is
through the ascending aorta. As the right atrium is
poorly visualised with this technique, venous cannula-
tion is percutaneous through the femoral vein (using a
Seldinger technique guided by transoesophageal
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Schedule of enrolment, intervention, and assessments for the MAVRIC trial
STUDY PERIOD
Enrolment Allocation Post-allocation Follow-up
TIMEPOINT
-26 weeks to 
day of 
surgery
Following 
confirmation 
of eligibility 
to day of 
surgery
Day of 
surgery
Post op
Day 1
Post op
Day 2
Post 
op
Day 3
Post 
op
Day 4
Post op
Day 5 
onwards 
until 
discharge
6 weeks 12 weeks
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Manubrium-limited 
ministernotomy X
Conventional 
median 
sternotomy
X
ASSESSMENTS:
Medical History X
Physical 
Examination X
Demographics X
Concomitant 
Medications X X X X X X X X X
U&Es X
Pregnancy test X
Full Blood Count X X X X X X X
Coagulation 
screen X X X
Inflammatory 
markers X X X
Echocardiogram X X
EQ-5D-3L X X X X
Pulmonary 
Function Tests X X X X
euroSCORE X
Transoesophageal 
Echocardiogram X
Wound dressing X X
In situ
X
removed
Pain score X X X X X X X
Fitness for transfer X X
Fitness for 
discharge X X X
Red Blood Cell 
transfusions X X X X X X X X
Blood product 
transfusions X X X X X X X X
Adverse Events X X X X X X X X
Re-operation X X X X X X X X
NHS resource use X X
Fig. 1 Schedule of enrolment, intervention and assessments for the MAVRIC trial
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echocardiography). Vacuum assist is used as necessary to
aid venous drainage. Antegrade cardioplegia is used for
myocardial protection, and venting is via the pulmonary
artery. A transverse aortotomy is performed, followed by
standard aortic valve insertion using interrupted nonpled-
geted braided sutures. The aortotomy is closed in a single
or double layer. One pericardial drain and ventricular
pacing wires are placed in all patients. Atrial wires are
placed if needed. These steps are performed prior to re-
moving the cross-clamp to facilitate the view of the right
atrium and ventricle. The sternum is closed with two
wires in the manubrium and two wires from the body of
the sternum up to the manubrium.
Conventional median sternotomy (control)
For the conventional technique, a standard median
sternotomy is performed using systemic normothermia.
Cannulation is via the ascending aorta with two-stage
right atrial cannulation for venous drainage. Venting of
the left ventricle is achieved via the pulmonary artery, and
myocardial protection is with cold blood antegrade cardi-
oplegia. All valves are inserted using interrupted sutures.
During the trial, both operations are performed in ac-
cordance with an agreed and standardised anaesthetic
protocol. Patients are given lorazepam as a pre-
medication, followed by anaesthesia with propofol, fen-
tanyl, rocuronium bromide and morphine. All patients
are given a total dose of tranexamic acid (TXA) at 30
mg/kg. Where patients have a pre-surgical creatinine
>200 mmol/L, the dose of TXA is halved to 15 mg/kg.
Prior to cardiopulmonary bypass, systemic anticoagula-
tion is achieved with heparin given at a dose that
achieves an activated clotting time (ACT) of greater than
400 seconds. Fresh frozen plasma (FFP) is administered
if the target ACT is not reached. During cardiopulmo-
nary bypass, haemoglobin (Hb) is kept at 60 g/L or
above. Haemofiltration followed by RBC transfusion may
be required to achieve this. Following cardiopulmonary
bypass (CPB), protamine will be administered to reverse
heparin, according to the dose of heparin given. Blood
products may be used intra-operatively in the presence
of excessive blood loss. RBC salvage will be used in all
patients.
All patients have the new aortic valve assessed at the end
of surgery using a transoesophageal echocardiogram (TOE).
Details of this, as well as any additional surgical intervention,
including conversion to conventional sternotomy from
manubrium-limited sternotomy, and any further TOE are
recorded.
Post-operative warfarin and aspirin administration
Post-operatively, all patients having a biological pros-
thesis begin 75 mg aspirin on the morning of the day
following surgery. All patients having a mechanical pros-
thesis commence on warfarin on the evening of the day
following surgery.
Post-operative assessments and procedures
The post-operative period (and trial protocol in rela-
tion to RBC and other blood product transfusions)
begins once the patient has been admitted to the Car-
diac Intensive Care Unit (CICU). Residual blood after
cardiopulmonary bypass that has been bagged may all
be given as a transfusion intravenously; the transfu-
sion of this residual blood is commenced prior to
CICU admission.
Blood and blood product usage following surgery
The post-operative RBC transfusion and blood
product transfusion processes for this trial begin from
the point of admission to the CICU. All residual
blood from the CPB reservoir and cell salvaged blood
is returned to the patient; the following transfusion
processes are implemented following complete trans-
fusion of this blood and continue until a patient is
discharged following their index operation.
Trial patients receive a RBC transfusion if at least one
of the following criteria is met:
 Their Hb is <80 g/L.
 A diagnosis of post-operative bleeding is made as
defined by ≥400 ml/h blood loss or ≥100 ml/h for ≥
4 h with Hb ≥80 g/L.
 Blood loss leading to haemodynamic instability
occurs irrespective of thromboelastography (TEG)
and clotting profile results.
Trial patients receive a blood product transfusion if
both of the following criteria are met:
 A diagnosis of post-operative bleeding occurs as de-
fined by ≥400 ml/h blood loss or ≥100 ml/h for ≥ 4 h.
 TEG or coagulation guided transfusion is indicated.
Fig. 2 Division and transection of the sternum in a manubrium-limited
ministernotomy
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Clinicians are able to transfuse, or decide not to trans-
fuse, in violation of the protocol parameters; their reason
for doing so will be recorded.
Outcomes
Primary outcome
The primary outcome is the proportion of patients who
receive a RBC transfusion post-operatively and within 7
days of AVR surgery.
Secondary outcomes
Secondary outcomes are:
 The proportion of patients who receive a RBC
transfusion during the intra-operative period and
the entire post-operative hospital stay
 The mean number of RBC units transfused during
the intra-operative period, post-operative period
(within the 7 days following AVR surgery) and the
entire post-operative hospital stay
 The proportion of patients receiving blood product
transfusions during the intra-operative period, within
the 7 days following AVR surgery and during the entire
hospital stay
 The mean number of blood product transfusions
received during the intra-operative period, within
the 7 days following AVR surgery and during the en-
tire hospital stay
 Mean post-operative blood loss (millilitres) measured
from chest drains at 6 and 12 hours, and at the time
of drain removal, following AVR surgery
 Operative success as defined by transthoracic
echocardiographic assessment of left ventricular
function, and degree of aortic regurgitation, within 6
weeks of AVR surgery
 Mean post-operative changes in haemoglobin (Hb)
within the index hospital stay
 Mean post-operative changes in inflammatory
markers on admission to CICU and on day 1
following AVR surgery
 Proportion of patients reporting moderate or severe
post-operative sternal wound pain, measured daily
using an 11-point numerical rating scale developed by
the trial team, until patient is fit for hospital discharge,
and at 6 and 12 weeks following AVR surgery
 Rates of re-operation following index AVR surgery
until 12 weeks
 Rate of conversion to conventional AVR during
index surgery
 Changes in forced expiratory volume and forced
vital capacity on days 3 and 4 and at 6 weeks
following AVR surgery
 EuroQoL EQ-5D-3L [21] scores, captured at
baseline and on day 2, and 6 weeks and 12 weeks
following AVR surgery, will be converted to health
status scores using the value set (time trade-off) [22]
and provide patient-level quality-adjusted life year
(QALY) estimates as a health outcome [23]. The EQ-
5D-3L is a validated, self-reported outcome measure
consisting of five dimensions: mobility, self-care, usual
activity, pain/discomfort, anxiety/depression. Each
dimension has three levels of response.
 Mean time at which patients are fit for discharge
from hospital following AVR surgery
 Health care utilisation during hospital stay and
following discharge to 12 weeks, from medical note
review, GP records and patient reports
 Cost and cost effectiveness estimated from QALY
estimates and health care utilisation valued using
national reference costs to 12 weeks
 Rates of related adverse events during the 12 weeks
following surgery including severity.
Participant timeline
Patients are followed for 12 weeks, with follow-up at 6
weeks and 12 weeks after discharge from hospital fol-
lowing their index AVR operation. Figure 3 provides a
flow chart of the patient pathway in the MAVRIC trial.
Sample size calculation
This trial will determine if manubrium-limited minister-
notomy is an appropriate clinical alternative to the exist-
ing operation (conventional sternotomy) in terms of
RBC transfusion requirements in the 7 days following
index surgery. Currently, there is clinical and policy
equipoise with no intention to extend the use of the new
procedure until high-quality randomised controlled trial
evidence is available.
Using Fisher’s exact test, 90% power, 5% alpha, 260
patients are required to detect a 17% reduction in the
proportion of patients requiring RBC transfusion (13%
compared with 30%), using a two-sided test. Recruit-
ment will continue until the target sample size is
reached and 260 patients are contributing to the primary
outcome.
Recruitment
Patients undergoing isolated AVR surgery will be identi-
fied at the point of referral or from the inpatient waiting
list by the clinical team, and will be approached by a
member of the research team about participation in
MAVRIC. Patients will be consented by a Consultant
Cardiothoracic Surgeon or a Surgical Registrar.
Allocation
Following consent, eligible patients are randomised to
receive AVR by manubrium-limited ministernotomy or
by conventional sternotomy following confirmation of
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eligibility. Randomisation is made using a permuted
block randomisation, stratified by logistic EuroSCORE
[24] (low risk 0–3.50%, moderate risk 3.51–7.5% and
high risk >7.5%) and by pre-operative Hb (90–125 g/L,
126–140 g/L, >140 g/L). A web-based randomisation
system, managed by Durham Clinical Trials Unit
(DCTU), will ensure concealment of allocation.
Blinding
This is a single-blind trial. Patients are not informed of
the type of sternotomy they are planned to receive, or
do receive, until completion of the pain assessment on
day 2 following their operation. To enable blinding post-
operatively, all patients have a trial-specific opaque dress-
ing applied to their sternal wound and to their groin.
Measures taken to avoid bias
This trial incorporates a number of methods to avoid
bias:
 Concealment of allocation will be achieved
through a web-based randomisation system, de-
scribed above, managed by DCTU. Named clinical
research team members enter a minimum data
set per patient before individual allocation to type
of sternotomy is provided.
 Three consultant cardiothoracic surgeons perform
all operations as part of this trial. Each is expert in
both techniques and does not delegate to other
trainee or consultant surgeons.
 Criteria for blood and blood product transfusions
are detailed in the protocol and followed for all
patients. Clinical staff members in all cardiothoracic
wards follow this protocol. Where clinical need
requires blood to be given outside of the protocol,
this is documented and described. The trigger for all
transfusions is recorded.
 Patients are blind to the sternotomy procedure, both
planned and received, for 2 days following their
index surgery. All have an opaque dressing applied
to both the sternum and the groin to facilitate
blinding; these are only removed, and the patient
informed, following their day 2 trial assessments
unless clinical need requires earlier removal. Sternal
wound pain is assessed using an 11-point numerical
rating scale, with all analgesic medication taken in
the preceding 4 hours recorded.
 Fitness for discharge is measured using defined
physiotherapy and clinical criteria; these are
assessed daily from day 3 by a research team
physiotherapist and by the surgical research team.
The date that both physiotherapy and clinical
criteria are met is defined as the date the patient
is fit for discharge. The date of actual discharge is
also recorded.
 Where patients choose to withdraw from the study
prior to 7 days following their index surgery,
permission is sought to continue data collection to
support analysis of the primary endpoint.
Data collection methods
Baseline assessments
In addition to usual care procedures, baseline assess-
ments take place following consent and prior to surgery.
Fig. 3 Flow chart of the patient pathway for the MAVRIC trial
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Cardiovascular and significant current and past medical
history
A full medical history is recorded for each patient at
baseline and includes details of all clinically significant
past medical conditions and all clinically significant on-
going medical conditions including full cardiovascular
history.
Physical assessment
A physical assessment of height (measured in centi-
metres) and weight (measured in kilograms) determines
body mass index.
Current medications
A full list of the generic names of relevant medications
taken by the patient is recorded within 14 days before
surgery. The information includes frequency and dose.
Changes or additions are recorded from baseline until
the 12-week follow-up visit.
For patients in both trial arms, pre-operative antiplate-
let drugs (including clopidogrel and aspirin) and antico-
agulants (including heparin and warfarin) are
discontinued 5 days prior to surgery. The exception is
aspirin, which is stopped 5 days prior to surgery where
possible; however, continuation until the day of surgery
does not exclude a patient from the trial, and is re-
corded. These drugs may be re-started following surgery
at the discretion of the clinical team. Dates for re-
starting medications are recorded.
International normalized ratio (INR) checks for patients
taking warfarin
Patients on warfarin have their INR checked as part of
routine care on admission to hospital for their index sur-
gery. Where an INR is ≤1.5, the patient proceeds to sur-
gery. Where a patient’s INR is >1.5, appropriate
treatment may be given and surgery may need to be de-
layed. The INR for patients taking warfarin must be ≤1.5
prior to surgery.
Demographic information
The following demographic data are recorded:
 Age
 Gender
 Ethnicity.
Blood tests
Blood tests are taken within 14 days prior to surgery and
prior to randomisation:
 Urea and electrolytes (sodium, potassium, creatinine,
urea)
 Pregnancy test
 Full blood count (haemoglobin, haematocrit,
platelets, white cell count)
 Coagulation screen (prothrombin time (PT),
prothrombin time ratio (PTR), activated partial
thromboplastin time (APTT), activated partial
thromboplastin time ratio (APTTR)
 Inflammatory markers.
Out of normal range blood parameters are assessed by
the clinical team to confirm that there are no clinically
significant findings that would affect continuation in the
trial. The value of haemoglobin taken up to 14 days pre-
surgery is used as a stratifying variable for
randomisation.
Patients also have blood samples (stored as plasma)
taken pre-operatively, on admission to CICU and 24 h
post-operatively. These are analysed to explore the fol-
lowing null hypotheses:
1. That there will be no difference between peri-
operative inflammatory markers (IL-6, IL-8, IL-10)
and markers of endothelial inflammation (ICAM-1
or CD62E) between those undergoing AVR via
manubrium-limited ministernotomy when compared
to AVR via conventional sternotomy
2. That there is no correlation between the number
and proportion of patients who receive a RBC
transfusion and the number of units transfused
and peri-operative inflammatory markers (IL-6,
IL-8, IL-10).
Echocardiogram
Results from the latest echocardiogram (echo) pre-
surgery are recorded. If an echo has not been done
within 39 weeks (9 months) of consent, this is repeated
at baseline.
Pulmonary function tests
Pulmonary function tests of forced expiratory volume
(FEV1) and forced vital capacity (FVC) are performed at
baseline with patients sitting for both assessments.
These assessments are repeated on days 3 and 4, and at
6 weeks following discharge from hospital after their
index surgery.
EuroSCORE
Logistic EuroSCORE [24] is determined prior to ran-
domisation to be used as a stratifying variable, with the
score recorded. The elements that determined the logis-
tic EuroSCORE pre-operatively are also recorded. Euro-
SCORE II [25] and the elements that determine this
score are also recorded.
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Quality of life assessment (EuroQoL EQ-5D-3L [22])
Each patient completes the EuroQoL EQ-5D-3L [21]
questionnaires at baseline. If the patient is physically un-
able to complete the questionnaires, or the assessment is
being performed over the telephone, the research team
will administer them to the patient, who dictates their
answers. The details of who is recording the patient’s re-
sponses are noted. Questionnaires are repeated at day 2,
6 weeks and 12 weeks (3 months) following discharge
from hospital.
Assessment of pain
Pain is assessed within 14 days prior to index surgery
using an 11-point numerical rating scale. Pain is also
assessed post-operatively (daily from post-operative day
2 until the patient is deemed ‘fit for discharge’), and at
follow-up (6 and 12 weeks following discharge).
Retention of participants
Patients who withdraw have all data collected up until
the point of withdrawal included in the study except
where withdrawal is due to a related adverse event (AE),
in which case the patient is followed until a stable out-
come is achieved.
Data management
The study is managed by the Chief Investigator with
support from DCTU.
Study data are recorded in each patient’s medical notes
before being entered onto electronic Case Report Forms
(e-CRFs). Data entered into the e-CRF must be consist-
ent with the information in the medical notes. Discrep-
ancies are noted and explained. Un-anonymised data are
held on site in accordance with local Trust policies.
Patients are identified by a unique study number at en-
rolment. All data passed to DCTU have patient identi-
fiers removed, except date of birth, gender, ethnicity and
unique study ID. All data are handled in a confidential
manner by DCTU, the research team and by members
of the Data Monitoring Committee (DMC) and Trial
Steering Committee (TSC).
Statistical methods
The null hypothesis is that there will be no difference in
the proportion of patients receiving RBC transfusion
after manubrium-limited ministernotomy when com-
pared to conventional sternotomy for AVR.
This trial will determine if manubrium-limited minis-
ternotomy is an appropriate clinical alternative to the
existing operation (conventional sternotomy) in terms of
RBC transfusion requirements in the 7 days following
index surgery. An analysis of the primary endpoint will
be conducted using Fisher’s exact test. A sensitivity ana-
lysis will also be performed for the primary endpoint
using a logistic regression model to account for potential
confounders and stratification factors. Continuous out-
comes will be analysed using general linear models. Cor-
relation between repeated measures per patient will be
appropriately accounted for in the linear models where
applicable. Binary data will be analysed using logistic re-
gression where there are no repeated data per patient.
Repeated binary data will be analysed using generalised
estimating equations. Stratification factors and chance
baseline imbalances following randomisation will be ex-
plored for the primary and secondary outcomes.
Analysis will follow intention-to-treat principles with
patients analysed according to the surgery allocated by
randomisation and irrespective of surgery received, sub-
sequent management or events [26]. Every effort will be
made to retain and include all patients who receive sur-
gery as part of the trial.
A prospective economic evaluation is integrated into
the trial design and applies an NHS perspective to the
inclusion of costs. Mechanisms of missingness within
the data will be explored, and multiple imputation
methods will be applied to impute missing data and
minimise bias. Imputation sets will be used in bivariate
analysis of costs and QALYS to generate incremental
cost per QALY estimates and credible intervals [27–29].
It is anticipated that incremental costs and benefits will
be captured within the trial, although extrapolated
economic modelling will be considered if appropriate.
Findings will be presented on the incremental cost-
effectiveness ratio (ICER) plane and using cost-
effectiveness acceptability curves (CEACs).
Governance
The trial is overseen by a TSC, which includes an inde-
pendent chair and two other independent members (one
of whom is a patient). In addition, the trial has a DMC,
which meets 6 monthly, and oversees all ethical and
safety issues in accordance with a study-specific DAMO-
CLES charter [30] for DMCs. All members are inde-
pendent of the study team, although the Trial Manager,
Chief Investigator and some other members of the Trial
Management Group (TMG) attend the open sessions in
order to inform the DMC of trial progress.
Reporting of adverse events
AEs and serious adverse events (SAEs) are recorded and
reported from the time of index surgery until comple-
tion or withdrawal. SAEs are reported within 24 h of the
research team becoming aware of the event to the Spon-
sor. Where required, these events undergo expedited
reporting to the Research Ethics Committee. All AEs are
assessed for severity, causality, expectedness and serious-
ness by an Investigator; all are reviewed by the DMC.
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Dissemination
On-going patient and public involvement informs appro-
priate methods of dissemination to patients. Feedback
will be given to national surgical leads via the Society for
Cardiothoracic Surgeons in Great Britain and Ireland,
maximising the exposure of findings to cardiac surgeons
diagnosing and treating patients requiring AVR.
Findings will be presented at national specialist meet-
ings to raise awareness. We will engage directly with
surgeons and cardiothoracic units around the country to
share results. Data will be presented at the annual meet-
ing of the Society for Cardiothoracic Surgeons in Great
Britain and Ireland, and we anticipate this to be the
main forum for disseminating findings from this study.
Discussion
This is the first trial to examine aortic valve replacement
via manubrium-limited ministernotomy versus conven-
tional sternotomy when comparing red blood cell trans-
fusion rates following surgery. MAVRIC will determine
if manubrium-limited ministernotomy should be
adopted as best practice for patients requiring AVR
surgery.
It was not possible to blind clinicians to the surgical
procedure provided, although transfusion decisions are
protocol-driven and should not be procedure-related.
The inclusion of patient blinding was in response to a
funding panel recommendation. It has been possible to
implement this through the use of opaque dressing,
which means that patient-reported pain scores at 2 days
will be blinded. We will assess the effectiveness of blind-
ing by inviting patients to indicate which treatment they
think they have received before removing the dressings.
Surgical trials present significant challenges. The
strengths of this trial include a rigorous research design,
standardised surgery performed by experienced consult-
ant cardiothoracic surgeons, an agreed anaesthetic regi-
men, patient blinding and consultant-led patient
recruitment. Each discipline within the Cardiothoracic
Division at JCUH is supporting and collaborating with
the Chief Investigator. MAVRIC will demonstrate that
complex surgical trials can be delivered to exemplary
standards and provide the community with the know-
ledge required to inform future care for patients requir-
ing aortic valve replacement surgery.
Protocol version
This is approved version 5 of the trial protocol.
Trial status
The trial began recruiting in March 2014; the trial is due
to report in 2017.
Additional file
Additional file 1: SPIRIT 2013 checklist. (DOC 121 kb)
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